Results 221 to 230 of about 577,565 (357)

Expert Perspectives: Defining and managing progressive pulmonary fibrosis in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
‐‐
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Childhood and contemporaneous inflammation in depersonalisation and derealisation: Longitudinal evidence from the Avon Longitudinal Study of Parents and Children. [PDF]

Brain Behav Immun Health
Dilkes E, Gillmeister H, Daughters K.
europepmc   +1 more source

Conservation Reserve Program: Environmental Benefits Update

This paper presents the methodology, assumptions, and data used to generate regional and national environmental benefit estimates of the USDA’s Conservation Reserve Program (CRP).
Hansen, LeRoy T.
core  

Navigating adverse immunostimulation: A practical guide for clinical researchers

British Journal of Clinical Pharmacology, EarlyView.
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort, Anouk C. Meijs, Naomi B. Klarenbeek, Matthijs Moerland   +3 more
wiley   +1 more source

Systemic Inflammation and its association with functional impairment and mortality in patients with disease-related malnutrition: findings from the AFEDIN cohort. [PDF]

Front Nutr
Vidal-Casariego A, Milla SP, Gómez JJL, Almeida JMG, Aguilar IV, Baena JMG, Fernández CP, Riccardi PM, Prol AR, Luna PPG, Castro PP, Hernández NCI, Pérez LML, de Luis Román D.   +13 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Dynamic inflammatory biomarkers as prognostic indicators in advanced breast cancer patients receiving PD-1 inhibitors. [PDF]

Ther Adv Med Oncol
Wang N, Yi P, Lu Q, Zhong Y, Xue C, Zhang P, Wang S, Yuan Z, Shi Y, Chen H, Xu F, Jiang K.   +11 more
europepmc   +1 more source

Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul, H. Rob Taal, Jan Mazela, Ryszard Lauterbach, Irwin K. M. Reiss, Karel Allegaert, Robert B. Flint, Sinno H. P. Simons   +7 more
wiley   +1 more source

The Association of C-Reactive Protein-Triglyceride Glucose Index with Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction. [PDF]

J Inflamm Res
Wang T, Zhang G, Li Q, Liu Y, Zhao T, Che W, Xia J.   +6 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source